IGF-DES
Low EvidenceA truncated form of IGF-1 with high potency and rapid local activity at the site of administration.
What It Is
IGF-DES (Des(1-3) IGF-1) is a truncated variant of insulin-like growth factor-1 missing the first three N-terminal amino acids (Gly-Pro-Glu). This truncation virtually eliminates binding to IGF-binding proteins (IGFBPs), making IGF-DES the most potent form of IGF-1 available in terms of free bioactivity. Without IGFBP regulation, IGF-DES exhibits approximately 10× greater potency than native IGF-1 in cell proliferation assays and has a very short half-life (approximately 20–30 minutes), producing rapid but transient IGF-1R activation. IGF-DES was originally identified as a naturally occurring variant in human brain tissue, where it is thought to act in an autocrine/paracrine fashion. Its extreme potency and lack of IGFBP buffering make it particularly high-risk from a safety perspective — unregulated IGF-1R signaling promotes cell proliferation pathways implicated in tumor growth and progression. Research applications are primarily limited to in vitro cell biology and tissue engineering where precise, short-duration IGF-1R stimulation is needed. IGF-DES has no clinical trial history, is classified as prohibited by WADA, and is not FDA-approved for any indication.
Why Researchers Study It
Des(1-3) IGF-1 lacks the first three amino acids of native IGF-1, which eliminates binding to IGF-binding proteins entirely. This results in dramatically increased bioactivity at the IGF-1 receptor, making it a potent research tool for studying maximal IGF-1 receptor activation and its downstream effects on cell proliferation.
Proposed Mechanisms
- Binds IGF-1 receptor with full affinity but cannot be sequestered by IGF-binding proteins
- Approximately 10x more potent than native IGF-1 at receptor activation
- Stimulates rapid cell proliferation and protein synthesis
- Very short half-life concentrates activity at local injection site
Evidence Snapshot
Commonly Discussed Benefits
Researching IGF-DES? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Extremely potent growth factor
- Theoretical concerns about uncontrolled cell proliferation
- Very short half-life requires precise administration
- Not FDA-approved; limited human safety data
Comparisons
See how IGF-DES compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Ballard FJ. et al. — Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996 PubMed
Keep researching in the app
- Log IGF-DES to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
IGF-1 LR3
Medium EvidenceA modified form of IGF-1 with extended half-life, studied for muscle growth and tissue development.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
PEG-MGF
Low EvidenceA PEGylated splice variant of IGF-1 studied for muscle repair and satellite cell activation, with an extended half-life compared to native MGF.